Brian Belmontes
Amgen (United States)(US)Université Bourgogne Franche-Comté(FR)
Publications by Year
Research Areas
Cancer-related gene regulation, Growth Hormone and Insulin-like Growth Factors, Ovarian cancer diagnosis and treatment, Cancer, Hypoxia, and Metabolism, Cell death mechanisms and regulation
Most-Cited Works
- → AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies(2018)409 cited
- → Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models(2008)235 cited
- → AMG 479, a fully human anti–insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells(2009)131 cited
- → Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors(2021)110 cited
- → Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade(2017)104 cited
- → Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth(2010)75 cited
- → AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers(2024)56 cited
- → Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers(2023)55 cited
- → Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment(2021)54 cited
- → Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy(2014)47 cited